Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

UCB SA (UNC.F)

Compare
198.15
+9.35
+(4.95%)
As of 8:12:58 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UNC.F

Recent News: UNC.F

View More
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com yesterday
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
PR Newswire 6 days ago
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
PR Newswire last month
USNA or UCBJY: Which Is the Better Value Stock Right Now?

USNA or UCBJY: Which Is the Better Value Stock Right Now?
Zacks 2 months ago
Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study

Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study
The Wall Street Journal 2 months ago
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
PR Newswire 2 months ago
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
PR Newswire 3 months ago
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Benzinga 3 months ago
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
PR Newswire 3 months ago
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
GlobeNewswire 3 months ago
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
PR Newswire 3 months ago
View More
Waiting for permission
Allow microphone access to enable voice search

Try again.